Business Context and Reporting Period
Company: SBC Medical Group Holdings Inc (SBC)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended September 30, 2025
Business Overview: SBC provides comprehensive management services to medical corporations and clinics, primarily in Japan, under the "Shonan Beauty Clinic" brand. Services include franchising, procurement, management consulting, and rental services. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $43.35 million | $53.08 million | $134.04 million | $160.99 million |
| Gross Profit | $30.61 million | $43.24 million | $98.36 million | $122.18 million |
| Gross Margin | 70.6% | 81.5% | 73.4% | 75.9% |
| Net Income (Attributable to SBC) | $12.82 million | $2.83 million | $36.79 million | $40.08 million |
| Operating Cash Flow | N/A | N/A | $(27.30) million | $27.89 million |
| Cash and Equivalents | $127.43 million | N/A | $127.43 million | $137.39 million |
| Total Debt (Long-term + Current) | $21.12 million | N/A | $21.12 million | $6.60 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 18.3% in Q3 2025 compared to Q3 2024. This was driven by a 36.7% drop in franchising revenue and a 23.7% drop in procurement revenue, largely due to a revised fee structure effective April 2025 and reduced orders for medical materials.
- Profitability Improvement (Q3): Despite lower revenue, Net Income attributable to SBC surged 352.7% to $12.82 million in Q3 2025. This was primarily due to a $12.8 million reduction in operating expenses, specifically the elimination of a one-time $12.8 million stock-based compensation expense recognized in Q3 2024.
- Profitability Decline (YTD): On a year-to-date basis, Net Income decreased 8.2% to $36.79 million. This decline was offset by a significant non-operating gain of $8.75 million from the redemption of life insurance policies in 2025, which was not present in the prior year.
- Cash Flow Reversal: Operating cash flow swung from a positive $27.9 million in YTD 2024 to a negative $27.3 million in YTD 2025. The primary drivers were a $28.0 million increase in accounts receivable from related parties and a $19.9 million decrease in income tax payable.
- Debt Increase: Total long-term loans increased significantly from $6.60 million at year-end 2024 to $21.12 million as of September 30, 2025, reflecting new borrowings for working capital.
Guidance, Outlook, and Risks
- Strategic Acquisitions: On November 13, 2025, the Board approved a tender offer and off-market transfer to acquire a controlling interest in Waqoo, Inc., a Tokyo Stock Exchange-listed company. The company intends to consolidate Waqoo to accelerate R&D in regenerative medicine and orthopedics.
- Share Repurchases: The company completed a $5.0 million share repurchase program in July 2025, purchasing 1,034,308 shares.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to identified material weaknesses that remained un-remediated from the prior year.
- Related Party Concentration: A significant portion of revenue and receivables is derived from related parties (Medical Corporations where CEO relatives are members). As of September 30, 2025, related party receivables totaled $58.6 million.
- Foreign Exchange: The company is exposed to JPY/USD fluctuations. The appreciation of the Yen in 2025 provided a favorable impact of approximately $455,000 on Q3 revenue.
Investor Verification Checklist
- Related Party Transactions: Verify the sustainability of revenue streams from related parties, which accounted for $39.6 million of $43.4 million in Q3 revenue.
- Internal Control Remediation: Review the specific remediation plan for the material weaknesses in disclosure controls and internal financial reporting.
- Waqoo Acquisition: Monitor the progress and financial impact of the pending acquisition of Waqoo, Inc., including the tender offer settlement expected in December 2025.
- Operating Cash Flow: Assess the company's ability to reverse the negative operating cash flow trend, which was heavily impacted by working capital changes with related parties.
- Fee Structure Impact: Evaluate the long-term impact of the April 2025 fee structure revision on franchising and management service revenues.